• is an online educational resource on the genetics of cystic fibrosis (CF) and the role of CF transmembrane conductance regulator (CFTR) in normal human physiology as well as in CF.
  • The information contained herein is intended for healthcare professionals working within the European Union (EU).
  • The content of this website has been developed independently by a group of CF healthcare professionals and is for general information purposes only.
  • All of the information about CFTR and CFTR modulators has been obtained from referenced sources and is in the public domain.
  • This website is not intended to promote or advocate a particular course of treatment or any specific drug, whether licensed or unlicensed, nor is it intended to imply or suggest that any drug be used for any purpose other than that which for which it is licensed in the EU.


  • While we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information and related graphics, or products and treatments, contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
  • In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from, or in connection with, the use of this website.
  • Through this website you are able to link to other websites which are not under our control. We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
  • Every effort is made to keep the website up and running smoothly. However, we take no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.

Please see the full Terms & Conditions before using this website.


I have read and understood the above

Drug & research development » Clinical trials » NCT01910415

Phase 1, QT/QTC Interval Study in Healthy Subjects

Official title: A Phase 1, Randomized, Placebo and Active Controlled, Double-Blind, Parallel, Electrocardiogram Study to Evaluate the Effect of Lumacaftor in Combination With Ivacaftor on the QT/QTc Interval in Healthy Subjects

Clinical Trials gov number: NCT01910415

Click on the tabs to move through the sequence.

Purpose: To evaluate the effect of multiple doses of VX-809 in combination with ivacaftor on cardiac repolarization, as detected by QT/QTc interval corrected for heart rate in healthy subjects.

Phase: 1

Type: Interventional, randomized, double-blind, factorial assignment

Study sponsor: Vertex Pharmaceuticals Incorporated

  • Subjects must be willing and able to comply with scheduled visits, treatment plan, lifestyle guidelines, laboratory tests, contraceptive guidelines, and other study procedures.
  • Subjects must be healthy, as defined by no clinically relevant abnormalities identified by a detailed medical history, physical examination, including blood pressure and pulse rate measurement, and 12 lead ECG.
  • Subjects must weigh >50kg

Ivacaftor, Lumacaftor, moxifloxacin hydrochloride

Geographical Location

Number of Participants
101-1000 (18-55 years)

Primary Endpoint

Part A

  • Safety and tolerability of lumacaftor as measured by standard 12-lead ECGs, adverse events, vital signs, spirometry, and clinically significant laboratory assessments (7 days)

Part B

  • Time matched, baseline-adjusted change in QTcF intervals obtained from a continuous ECG recording over a 24 hour interval after administration of a therapeutic and supratherapeutic dose of lumacaftor in combination with ivacaftor (7 days)

Secondary Endpoint

Part A

  • PK parameters of lumacaftor and M28-lumacaftor in plasma including Cmax and AUC (up to 11 days)

Part B

  • Time-matched, baseline-adjusted QTcF intervals obtained after a single 400-mg dose of moxifloxacin (up to 14 days)
  • Time-matched, baseline-adjusted non-QT interval parameters obtained from a continuous ECG recording over a 24-hour interval (up to 14 days)
  • PK parameters of lumacaftor, M28-lumacaftor, ivacaftor, M1-ivacaftor, and M6-ivacaftor including Cmax and AUC (up to 15 days)
  • PK/PD relationship between plasma concentration and QT/QTc interval (up to 14 days)
  • Safety and tolerability of lumacaftor in combination with ivacaftor as measured by standard 12-lead ECGs, AEs, vital signs, and clinical significant laboratory results (up to 24 days)

Click on the tabs to move through the sequence.

  • Experimental: Part A

Will consist of up to 4 cohorts with subjects receiving lumacaftor or placebo for 7 days.

Cohort 1: 600 mg lumacaftor once a day
Cohort 2: 1000 mg lumacaftor once a day
Cohort 3: 1200 mg lumacaftor once a day

  • Experimental: Part B

Will consist of 3 cohorts. All cohorts will be dosed in parallel.

Cohort A will receive 600 mg Lumacaftor once a day plus 250 mg Ivacaftor twice a day for 7 days. From day 8-14 subjects will receive a supratherapeutic dose of Lumacaftor (TBD) plus 450 mg Ivacaftor twice a day.

Cohort B will receive lumacaftor and ivacaftor matching placebo for 14 days Cohort C will receive a single dose of 400 mg moxifloxacin on day 14

View Trial Results